Embecta Corp.
NASDAQ:EMBCDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $345.06M
- Beta
- 0.81
- P/E (TTM)
- 1.6
- EPS (TTM)
- $1.92
- Dividend yield
- 14.79%
Volume 0.72M
Average 1.95M
EMBC Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Embecta Corp.NASDAQ: EMBC
Cash & Equivalents · Q2 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 11.7% from a year ago
Cash & equivalents stood at $184.9M at the end of Q2 FY2026, down 11.7% from a year earlier and down 9.5% from the prior quarter. Over 3 fiscal years it compounded at -12.0% a year.
Context
- Cash & equivalents amounted to 18.0% of total assets at the end of Q2 FY2026, down 0.7 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -11.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 225.5M USD
- Year-over-year change
- -15.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 225.5M | -15.7% |
| FY2024 | 2024-09-30 | 267.5M | -18.0% |
| FY2023 | 2023-09-30 | 326.3M | -1.4% |
| FY2022 | 2022-09-30 | 330.9M | — |
| FY2021 | 2021-09-30 | 0 | — |
Cash & Equivalents vs competitors
How EMBC compares with its peers on the latest reported figures
- EMBC's Mar 2026 cash & equivalents of $184.9M is the 3rd highest of the 11 companies compared; the peer median is $134.98M.
- Its year-over-year change of -11.7% is the 8th highest of 11, against a peer median of +2.3%.
- Cash & equivalents amounts to 18.0% of total assets for EMBC, versus a peer median of 22.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $373.64M | +447.8% | -10.1% | 70.1% | |
| Mar 2026 | $276.09M | +0.9% | -34.9% | 26.9% | |
| Mar 2026 | $184.9M | -11.7% | -12.0% | 18.0% | |
| Mar 2026 | $166.01M | -32.7% | -6.9% | 8.8% | |
| Mar 2026 | $160.3M | +7.5% | -31.6% | 12.1% | |
| Mar 2026 | $145.56M | -10.3% | +16.2% | 66.3% | |
| Mar 2026 | $124.4M | +35.5% | +38.0% | 18.5% | |
| Mar 2026 | $110.73M | +61.3% | +64.4% | 78.5% | |
| Mar 2026 | $73.59M | +3.7% | +11.7% | 22.6% | |
| Jun 2026 | $70.09M | -74.0% | -30.0% | 11.6% | |
| Mar 2026 | $64.11M | -30.2% | -30.5% | 21.8% | |
| Peer median (excluding EMBC) | $134.98M | +2.3% | -8.5% | 22.2% | |
Competitors are the stored peer set for EMBC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 0 | 330.9M | 326.3M | 267.5M | 225.5M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 150.6M | 23.4M | 17.9M | 248M | 148.9M |
| Inventory | 118M | 122.8M | 152.1M | 171.5M | 178.6M |
| Other Current Assets | 200K | 109.7M | 142.4M | 74M | 3.1M |
| Total Current Assets | 292M | 664.7M | 749.1M | 761M | 631.4M |
| Property, Plant & Equipment (Net) | 451M | 301.6M | 323.2M | 290.4M | 48.5M |
| Goodwill | 16M | 15.7M | 15.6M | 15.6M | 15.4M |
| Intangible Assets | 18M | 8.9M | 9.1M | 8.1M | 7M |
| Long-term Investments | (11.4M) | (95.5M) | 0 | 0 | 0 |
| Tax Assets | 11.4M | 95.5M | 0 | 0 | 20.2M |
| Other Non-current Assets | 11M | 95.5M | 117.4M | 210.2M | 368.4M |
| Total Non-current Assets | 496M | 421.7M | 465.3M | 524.3M | 459.5M |
| Total Assets | 788M | 1.09B | 1.21B | 1.29B | 1.09B |
| Account Payables | 54.2M | 41.4M | 53.5M | 91M | 74.2M |
| Short-term Debt | 1M | 9.5M | 9.5M | 9.5M | 12.9M |
| Tax Payables | 0 | 27.2M | 33.6M | 26.7M | 0 |
| Deferred Revenue | 0 | 0 | 33.6M | 0 | 0 |
| Other Current Liabilities | 0 | 198M | 33.6M | 0 | 115.2M |
| Total Current Liabilities | 164M | 301M | 353.5M | 374M | 261.5M |
| Long-term Debt | 0 | 1.6B | 1.59B | 1.57B | 1.39B |
| Deferred Tax Liabilities | 0 | 46.1M | 0 | 11.9M | 62.6M |
| Deferred Revenue (Non-current) | 0 | (46.1M) | 0 | 0 | 0 |
| Other Non-current Liabilities | 26.7M | 41.8M | 57.2M | 42.2M | 63.2M |
| Total Non-current Liabilities | 29.7M | 1.68B | 1.68B | 1.65B | 1.48B |
| Total Liabilities | 194M | 1.98B | 2.04B | 2.02B | 1.74B |
| Common Stock | 865M | 600K | 600K | 600K | 600K |
| Retained Earnings | 0 | (577.1M) | (541.1M) | (498.6M) | (445.6M) |
| Accumulated OCI | (271M) | (324.9M) | (309.1M) | (292.8M) | (285.6M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 594M | (891.4M) | (821.7M) | (738.3M) | (650.6M) |
| Total Debt | 4.1M | 1.64B | 1.64B | 1.61B | 1.43B |
| Net Debt | 4.1M | 1.31B | 1.31B | 1.34B | 1.2B |
Embecta Corp.
NASDAQ:EMBC
Intrinsic Alpha fair value
Locked
Current Price
$6.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.